J D Talley|J W Hurst - JoVE Visualize

Showing results (101-110 of 110) with videos related to

Pageof 11

Sort By:

You have reached the last page of results.This site can display upto 110 results.

The American Journal of Cardiology|March 1, 1997

Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon PumpJ D Talley, E M Ohman, D B Mark, et al.

The New England Journal of Medicine|August 26, 1999

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic ShockJ S Hochman, L A Sleeper, J G Webb, et al.

The American Journal of Cardiology|November 13, 2001

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.

The American Journal of Cardiology|March 18, 1999

Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplastyJ C Blankenship, M W Krucoff, S W Werns, et al.

Circulation|August 15, 1996

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC InvestigatorsD B Mark, J D Talley, E J Topol, et al.

The American Journal of Cardiology|August 1, 1978

Value of coronary bypass surgery. Controversies in cardiology: Part IJ W Hurst, S B King, R B Logue, et al.

Circulation|February 18, 1997

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.

Journal of the American College of Cardiology|June 17, 1998

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.

Circulation|May 31, 2001

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.

Controlled Clinical Trials|December 10, 1999

A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans AffairsD A Morrison, G Sethi, J Sacks, et al.

Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:

Pageof 11

You have reached the last page of results.This site can display upto 110 results.

The American Journal of Cardiology|March 1, 1997

Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon PumpJ D Talley, E M Ohman, D B Mark, et al.

The New England Journal of Medicine|August 26, 1999

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic ShockJ S Hochman, L A Sleeper, J G Webb, et al.

The American Journal of Cardiology|November 13, 2001

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.

The American Journal of Cardiology|March 18, 1999

Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplastyJ C Blankenship, M W Krucoff, S W Werns, et al.

Circulation|August 15, 1996

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC InvestigatorsD B Mark, J D Talley, E J Topol, et al.

The American Journal of Cardiology|August 1, 1978

Value of coronary bypass surgery. Controversies in cardiology: Part IJ W Hurst, S B King, R B Logue, et al.

Circulation|February 18, 1997

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.

Journal of the American College of Cardiology|June 17, 1998

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.

Circulation|May 31, 2001

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.

Controlled Clinical Trials|December 10, 1999

A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans AffairsD A Morrison, G Sethi, J Sacks, et al.

Pageof 11